Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

September 30, September 30, 2009 2008(*) 2009 2008(*) Net revenue $21,425 $18,997 $68,347 $51,799 Cost of services 9,796 8,596 28,675 24,465 ----- ----- ------ ------ Gross profit 11,629 10,401 39,672 27,334 Operating expenses: Sales and marketing 4,194 2,634 13,116 7,664 General and administrative 6,030 3,377 17,074 13,289 Bad debt 4,214 4,107 9,483 7,734 Research and development 282 98 805 321 --- --- --- --- Total operating expenses 14,720 10,216 40,478 29,008 ------ ------ ------ ------ Income (loss) from operations (3,091) 185 (806) (1,674) ------ --- ---- ------ Interest expense, net 144 2,399 4,056 5,747 --- ----- ----- ----- Loss from continuing operations before income taxes (3,235) (2,214) (4,862) (7,421) Income tax benefit (expense) - - 599 (6) Income from discontinued operations, net of income taxes - - 901 - --- --- --- --- Net loss (3,235) (2,214) (3,362) (7,427) Series A preferred stock beneficial conversion feature - - (4,290) -
'/>"/>
SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... SAN DIEGO, March 29, 2011 Marshall Edwards, Inc.(Nasdaq: ... the clinical development of novel therapeutics targeting cancer metabolism, ... inhibitor program has been accepted for a late-breaking poster ... Annual Meeting on Monday, April 4, 2011 at 1:00 ...
... EXTON, Pa., March 29, 2011 Morphotek®, Inc., ... it has entered into a collaboration and license ... the parties will collaborate to develop and commercialize ... monoclonal antibody to specifically detect human folate receptor ...
... DIEGO, March 29, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the American College of Cardiology (ACC) ... ACC:  Ernest N. Morial Convention Center (Expo Hall), New ...
Cached Biology Technology:Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 2Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 3Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 2Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 3
(Date:4/20/2014)... gift of germsgerms that help to kick-start the ... off infection, may paradoxically interrupt a newborn,s own ... to dangerous pathogens. , A new animal ... of Philadelphia (CHOP) sheds light on immunology in ... crucial role in fostering the rapid production of ...
(Date:4/18/2014)... X-ray crystallography and nuclear magnetic resonance imaging (NMR) to ... but such efforts have long been hampered by the ... molecule and often in ordered and crystalized form to ... peer into the structure of most molecules. , Harvard ... thing of the past. , A team of ...
(Date:4/18/2014)... as soon as they,re planted may be good news for ... In the wild, a plant whose seeds sprouted at the ... than just an insurance policy against late frosts or unexpected ... advantages too: Plants whose seeds put off sprouting until ... in a team of researchers working at the National Evolutionary ...
Breaking Biology News(10 mins):Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2
... Ill. (November 7, 2013) Chicago Botanic Garden researchers ... from the National Science Foundation to study the way ... to reproduce and survive. The floral scent may also ... role in the evolution and diversification of plant species. ...
... research on pond snails has revealed that high levels of ... Exeter and the University of Calgary trained snails and found ... were unable remember what they had learned. Previous research ... This study, published in the journal PLOS ONE , ...
... 6, 2013: In an article appearing in ... physician-researcher from the Touro College of Osteopathic Medicine has called ... a growth protein that could help predict an infant,s propensity ... findings in prior published studies, Touro researcher Gary Steinman, MD, ...
Cached Biology News:NSF awards Chicago Botanic Garden $1.54 million Dimensions in Biodiversity grant 2NSF awards Chicago Botanic Garden $1.54 million Dimensions in Biodiversity grant 3NSF awards Chicago Botanic Garden $1.54 million Dimensions in Biodiversity grant 4NSF awards Chicago Botanic Garden $1.54 million Dimensions in Biodiversity grant 5Stress makes snails forgetful 2Breastfeeding as a possible deterrent to autism -- a clinical perspective 2Breastfeeding as a possible deterrent to autism -- a clinical perspective 3